Publication: Treatment endpoints for chronic hepatitis D
Program
KU-Authors
KU Authors
Co-Authors
Metin, Olga
Editor & Affiliation
Compiler & Affiliation
Translator
Other Contributor
Date
Language
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Management of chronic hepatitis D (CHD) has entered a new era. In this new era, the virus entry inhibitor bulevirtide has received conditional approval as a treatment for compensated CHD. Three phase 3 studies with two new compounds are ongoing for the treatment of CHD. In this context, surrogate markers of treatment efficacy have been well defined for chronic hepatitis B (CHB) (7) and chronic hepatitis C (8) but not for CHD. The aim of this review is to give a perspective on treatment endpoints in CHD. For this, we took guidance from CHB studies and tried to make suggestions which differed according to finite versus prolonged treatment durations and also took into account the different characteristics of the new compounds.
Source
Publisher
Wiley
Subject
Gastroenterology, Hepatology
Citation
Has Part
Source
Liver International
Book Series Title
Edition
DOI
10.1111/liv.15447
item.page.datauri
Link
Rights
N/A